Being the first prospective and comprehensive imaging study in advanced HER2-positive breast cancer, we could not formulate a patient-oriented statistical hypothesis, which is why the primary endpoint of our study was a lesion-based analysis. This evidence concerns the gene ERBB2 and breast carcinoma.